In 2020, the Chinese NMPA established the Rare Diseases Registry. Since then, more foreign and local drug companies have been interested in getting their rare disease drugs into China. According to GlobalData’s Drugs Intelligence Database, there are now 378 drugs for rare... Read More
Japan’s MHLW is hoping to increase its fiscal year 2023 budget in a number of healthcare areas to promote better healthcare. An additional $3 million dollars is proposed to help cancer drug research via AI data analysis. This research is being done... Read More
Japan is the fastest aging country in the world. With about 125 million people now, their population is expected to decline to 90 million in 25 years. In an effort to increase their population, starting this month, Japan will begin to reimburse... Read More
This article was originally published on MedTech Intelligence. Japan is still the third largest medical device market in the world, after the United States and China. Many global device companies have established good businesses there and are making good profits. Foreign device... Read More
Chinese biotechnology firms have lagged behind their competitors for years in the use of artificial intelligence technologies. But increasingly, regulatory reforms are making it easier and cheaper for pharmaceutical companies in China to harness a vast trove of data collected from Chinese... Read More
Seeking to topple long-standing obstacles to drug innovation in Japan, pharmaceutical industry leaders in the country have outlined a slate of steps they propose the government take to foster research and development of new products, trim regulations and approval times, and speed... Read More
Advances in the use of artificial intelligence (AI) are fueling significant improvements in the field of radiology in Singapore, South Korea, and Australia, a new study has found. Eight in ten radiologists surveyed by health data firm Royal Phillips this year... Read More
With cancer a leading cause of death in Japan, the market for pharmaceuticals to treat tumors is expected to grow by 5% by 2023, and to represent one fifth of the market for pharmaceuticals by 2026. The prediction is part of a... Read More
Attracted by Shanghai government policies designed to encourage the development of the pharmaceutical industry, Western drug manufacturers are setting up shop in China’s financial hub. The biopharmaceutical firms are partnering with Chinese industry leaders, taking advantage of a reservoir of talented biopharma... Read More
With cancer a leading cause of death in Korea, the government plans to harness the power of big data to tackle the disease by increasing information sharing among healthcare institutions to bolster diagnosis, treatment, and research. At a meeting of the Korea... Read More